Novelix Pharmaceuticals touches roof on signing technology transfer agreement with GMBU e.V.
Novelix Pharmaceuticals is currently trading at upper limit of Rs. 44.15, up by 2.10 points or 4.99% from its previous closing of Rs. 42.05 on the BSE.
The scrip opened at Rs. 44.15 and has touched a high and low of Rs. 44.15 and Rs. 44.15 respectively. So far 20826 shares were traded on the counter.
The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 52.79 on 15-Jul-2025 and a 52 week low of Rs. 21.91 on 04-Nov-2024.
Last one week high and low of the scrip stood at Rs. 44.15 and Rs. 38.00 respectively. The current market cap of the company is Rs. 63.93 crore.
The promoters holding in the company stood at 52.75%, while Non-Institutions held 47.25% stake in the company.
Novelix Pharmaceuticals has signed a Technology Transfer agreement with GMBU e.V., Germany, marking a strategic collaboration to advance the large-scale production of Astaxanthin, a potent antioxidant with broad nutraceutical and pharmaceutical applications.
Under the agreement, GMBU e.V. will transfer its proprietary technology, expertise, and technical support services for the cultivation and scale-up of Haematococcus pluvialis to Novelix’s state-of-the-art laboratories at BTIC Park, Genome Valley, Hyderabad. The collaboration aims to bring Astaxanthin to market at a commercial scale for global supply.
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program, including the provision of algal strains, media components, laboratory equipment, and infrastructure. The company will also establish a GMP-certified production facility at its Techno Park site in Hyderabad to manufacture Astaxanthin in bulk, targeting key markets across Europe, North America, and India.
Novelix Pharmaceuticals is an innovation-driven biopharmaceutical company based in Hyderabad, India, focused on novel therapeutics, advanced biologics, and nutraceutical research.
